Have severe COPD? Learn how to manage your symptoms.

azithromycin

Pronunciation

Generic Name: azithromycin (a ZITH roe MYE sin)
Brand Name: Azithromycin 3 Day Dose Pack, Azithromycin 5 Day Dose Pack, Zithromax, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax, Zithromax IV

What is azithromycin?

Azithromycin is an antibiotic that fights bacteria.

Azithromycin is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, and sexually transmitted diseases.

Azithromycin may also be used for purposes not listed in this medication guide.

What is the most important information I should know about azithromycin?

You should not use this medication if you have ever had jaundice or liver problems caused by taking azithromycin.

What should I discuss with my healthcare provider before taking azithromycin?

You should not use this medication if you have ever had jaundice or liver problems caused by taking azithromycin. You should not use azithromycin if you are allergic to it or to similar drugs such as clarithromycin, erythromycin, or telithromycin.

To make sure azithromycin is safe for you, tell your doctor if you have:

  • liver disease;

  • kidney disease;

  • myasthenia gravis;

  • a heart rhythm disorder; or

  • a history of Long QT syndrome.

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether azithromycin passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

Do not give this medicine to a child younger than 6 months old.

Older adults may be more likely to have side effects on heart rhythm, including a life-threatening fast heart rate.

How should I take azithromycin?

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended. The dose and length of treatment with azithromycin may not be the same for every type of infection.

You may take most forms of azithromycin with or without food.

Take Zmax extended release liquid (oral suspension) on an empty stomach, at least 1 hour before or 2 hours after a meal.

To use the oral suspension single dose packet: Open the packet and pour the medicine into 2 ounces of water. Stir this mixture and drink all of it right away. Do not save for later use. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.

Throw away any mixed Zmax oral suspension that has not been used within 12 hours.

Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Azithromycin will not treat a viral infection such as the common cold or flu.

Store at room temperature away from moisture and heat. Throw away any unused liquid medicine after 10 days.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking azithromycin?

Do not take antacids that contain aluminum or magnesium within 2 hours before or after you take azithromycin. This includes Acid Gone, Aldroxicon, Alternagel, Di-Gel, Gaviscon, Gelusil, Genaton, Maalox, Maldroxal, Milk of Magnesia, Mintox, Mylagen, Mylanta, Pepcid Complete, Rolaids, Rulox, and others. These antacids can make azithromycin less effective when taken at the same time.

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking azithromycin and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

Avoid exposure to sunlight or tanning beds. Azithromycin can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Azithromycin side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • diarrhea that is watery or bloody;

  • headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats;

  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or

  • severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common side effects may include:

  • mild diarrhea;

  • mild stomach pain or upset;

  • dizziness; or

  • vaginal itching or discharge.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See also: Side effects (in more detail)

Azithromycin dosing information

Usual Adult Dose for Mycoplasma Pneumonia:

Community-acquired pneumonia:
Oral:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections

Extended-release suspension: 2 g orally as a single dose for mild to moderate infections

IV: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

Usual Adult Dose for Pneumonia:

Community-acquired pneumonia:
Oral:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections

Extended-release suspension: 2 g orally as a single dose for mild to moderate infections

IV: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

Usual Adult Dose for Legionella Pneumonia:

Community-acquired pneumonia: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

(Not approved by FDA)

Legionnaires' disease: 500 mg IV or orally once a day
Duration: 3 to 5 days for mild to moderate infections in immunocompetent patients; a longer treatment duration (at least 7 to 10 days or 3 weeks) may be necessary to prevent relapse in patients with more severe infections or with underlying comorbidity or immunodeficiency

Usual Adult Dose for Tonsillitis/Pharyngitis:

Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Recommended as an alternative (second-line therapy) in patients who cannot use first-line therapy

Usual Adult Dose for Sinusitis:

Acute bacterial sinusitis:
Immediate-release: 500 mg orally once a day for 3 days
Extended-release suspension: 2 g orally as a single dose for mild to moderate infections

Usual Adult Dose for Skin and Structure Infection:

Uncomplicated:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Adult Dose for Gonococcal Infection -- Uncomplicated:

Immediate-release:
Gonococcal urethritis and cervicitis: 2 g orally as a single dose

Centers for Disease Control and Prevention (CDC) recommendations:
Uncomplicated infections of the cervix, urethra, or rectum:
Recommended regimen: 1 g orally as a single dose plus ceftriaxone

Alternative regimens:
If ceftriaxone is not available: 1 g orally as a single dose plus cefixime plus test-of-cure in 1 week
If patient has severe cephalosporin allergy: 2 g orally as a single dose plus test-of-cure in 1 week

Uncomplicated infections of the pharynx:
Recommended regimen: 1 g orally as a single dose plus ceftriaxone

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Nongonococcal Urethritis:

Urethritis and cervicitis due to Chlamydia trachomatis:
Immediate-release: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Chlamydia Infection:

Urethritis and cervicitis due to Chlamydia trachomatis:
Immediate-release: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Cervicitis:

Urethritis and cervicitis due to Chlamydia trachomatis:
Immediate-release: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Chancroid:

Immediate-release: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Pelvic Inflammatory Disease:

500 mg IV once a day for 1 or 2 days followed by 250 mg (immediate-release formulation) orally once a day to complete a 7-day course of therapy

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Chronic Obstructive Pulmonary Disease -- Acute:

Acute bacterial exacerbations of COPD (mild to moderate):
Immediate-release: 500 mg orally once a day for 3 days
or
500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Adult Dose for Mycobacterium avium-intracellulare -- Prophylaxis:

Immediate-release:
Prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection: 1200 mg orally once a week; may be combined with the approved dosage regimen of rifabutin

(Not approved by FDA)

American Thoracic Society (ATS), CDC, National Institutes of Health (NIH), and Infectious Diseases Society of America (IDSA) recommendations for HIV-infected patients:
Primary prevention of disseminated MAC disease: 1200 mg orally once a week

Chronic maintenance therapy (secondary prophylaxis) for disseminated MAC disease: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen

Secondary prophylaxis is usually continued for life; however, discontinuation may be considered in patients with sustained immune recovery in response to antiretroviral therapy.

Usual Adult Dose for Mycobacterium avium-intracellulare -- Treatment:

Immediate-release:
Treatment of disseminated MAC infections in patients with advanced HIV infection: 600 mg orally once a day plus ethambutol

Other antimycobacterial drugs with in vitro activity against MAC may be added to this regimen at the physician's discretion.

(Not approved by FDA)

ATS, CDC, NIH, and IDSA recommendations:
Treatment of disseminated MAC infections in HIV-infected patients: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen

Combination therapy with at least 2 drugs is recommended. Chronic suppressive therapy (secondary prophylaxis) is recommended after initial therapy.

Usual Adult Dose for Granuloma Inguinale:

(Not approved by FDA)

CDC recommendations:
Immediate-release: 1 g orally once a week for at least 3 weeks and until all lesions have completely healed

This regimen is recommended as an alternative to doxycyline.

The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for STD Prophylaxis:

(Not approved by FDA)

CDC recommendations for sexual assault victims:
Immediate-release: 1 g orally as a single dose, in conjunction with metronidazole plus (ceftriaxone or cefixime)

Usual Adult Dose for Pertussis Prophylaxis:

(Not approved by FDA)

CDC recommendations for treatment and postexposure prophylaxis:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Adult Dose for Pertussis:

(Not approved by FDA)

CDC recommendations for treatment and postexposure prophylaxis:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Adult Dose for Lyme Disease -- Erythema Chronicum Migrans:

(Not approved by FDA)

IDSA recommendations:
Early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or advanced atrioventricular heart block:
Immediate-release: 500 mg orally once a day for 7 to 10 days

Azithromycin is recommended when first-line agents (oral doxycycline, amoxicillin, or cefuroxime) cannot be used. Patients should be monitored closely to ensure resolution of clinical manifestations.

Usual Adult Dose for Babesiosis:

(Not approved by FDA)

IDSA recommendations:
Immediate-release: 500 to 1000 mg orally as a single dose on the first day followed by 250 mg orally once a day for a total of 7 to 10 days, in combination with atovaquone

For immunocompromised patients, azithromycin 600 to 1000 mg orally per day may be used.

Usual Adult Dose for Bacterial Endocarditis Prophylaxis:

(Not approved by FDA)

American Heart Association (AHA) recommendations for patients allergic to penicillins:
Immediate-release: 500 mg orally as a single dose 30 to 60 minutes prior to the procedure

Usual Adult Dose for Toxoplasmosis:

(Not approved by FDA)

CDC, NIH, and IDSA recommendations for HIV-infected patients:
Immediate-release: 900 to 1200 mg orally once a day, in conjunction with pyrimethamine and leucovorin
Duration: At least 6 weeks; longer duration if disease is extensive or response is incomplete at 6 weeks

Azithromycin is recommended as an alternative regimen.

Usual Adult Dose for Typhoid Fever:

(Not approved by FDA)

Immediate-release: 1000 mg orally once a day for 5 days

Alternatively, a dosage of 8 to 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 days has been recommended.

Usual Adult Dose for Upper Respiratory Tract Infection:

(Not approved by FDA)

Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Adult Dose for Bronchitis:

(Not approved by FDA)

Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Pediatric Dose for Otitis Media:

Acute:
Immediate-release:
6 months or older: 30 mg/kg (maximum: 1500 mg/dose) orally as a single dose
or
10 mg/kg (maximum: 500 mg/dose) orally once a day for 3 days
or
10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

Usual Pediatric Dose for Mycoplasma Pneumonia:

Community-acquired pneumonia:
Oral:
Immediate-release:
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections

Extended-release suspension:
6 months or older:
Less than 34 kg: 60 mg/kg orally as a single dose for mild to moderate infections
34 kg or more: 2 g orally as a single dose for mild to moderate infections

16 years or older: 2 g orally as a single dose for mild to moderate infections

IV:
16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

Usual Pediatric Dose for Pneumonia:

Community-acquired pneumonia:
Oral:
Immediate-release:
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections

Extended-release suspension:
6 months or older:
Less than 34 kg: 60 mg/kg orally as a single dose for mild to moderate infections
34 kg or more: 2 g orally as a single dose for mild to moderate infections

16 years or older: 2 g orally as a single dose for mild to moderate infections

IV:
16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

Usual Pediatric Dose for Legionella Pneumonia:

Community-acquired pneumonia:
16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy

Usual Pediatric Dose for Tonsillitis/Pharyngitis:

Immediate-release:
2 years or older: 12 mg/kg (maximum: 500 mg/dose) orally once a day for 5 days
16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Recommended as an alternative (second-line therapy) in patients who cannot use first-line therapy

Usual Pediatric Dose for Sinusitis:

Acute bacterial sinusitis:
Immediate-release:
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally once a day for 3 days
16 years or older: 500 mg orally once a day for 3 days

Extended-release suspension:
16 years or older: 2 g orally as a single dose for mild to moderate infections

Usual Pediatric Dose for Skin and Structure Infection:

Uncomplicated:
Immediate-release:
16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Pediatric Dose for Gonococcal Infection -- Uncomplicated:

Immediate-release:
Gonococcal urethritis and cervicitis:
16 years or older: 2 g orally as a single dose

(Not approved by FDA)

CDC recommendations for children weighing greater than 45 kg and adolescents:
Uncomplicated infections of the cervix, urethra, or rectum:
Recommended regimen: 1 g orally as a single dose plus ceftriaxone

Alternative regimens:
If ceftriaxone is not available: 1 g orally as a single dose plus cefixime plus test-of-cure in 1 week
If patient has severe cephalosporin allergy: 2 g orally as a single dose plus test-of-cure in 1 week

Uncomplicated infections of the pharynx:
Recommended regimen: 1 g orally as a single dose plus ceftriaxone

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Nongonococcal Urethritis:

Immediate-release:
Urethritis and cervicitis due to C trachomatis:
16 years or older: 1 g orally as a single dose

(Not approved by FDA)

CDC recommendations:
Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Chlamydia Infection:

Immediate-release:
Urethritis and cervicitis due to C trachomatis:
16 years or older: 1 g orally as a single dose

(Not approved by FDA)

CDC recommendations:
Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Cervicitis:

Immediate-release:
Urethritis and cervicitis due to C trachomatis:
16 years or older: 1 g orally as a single dose

(Not approved by FDA)

CDC recommendations:
Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Chancroid:

Immediate-release:
16 years or older: 1 g orally as a single dose

(Not approved by FDA)

American Academy of Pediatrics (AAP) recommendations:
Infants and children weighing less than 45 kg: 20 mg/kg (maximum: 1 g/dose) orally as a single dose
Children weighing 45 kg or more and adolescents: 1 g orally as a single dose

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Pelvic Inflammatory Disease:

16 years or older: 500 mg IV once a day for 1 or 2 days followed by 250 mg (immediate-release formulation) orally once a day to complete a 7-day course of therapy

The patient's sexual partner(s) should also be evaluated/treated.

Usual Pediatric Dose for Chronic Obstructive Pulmonary Disease -- Acute:

Acute bacterial exacerbations of COPD (mild to moderate):
Immediate-release:
16 years or older: 500 mg orally once a day for 3 days
or
500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5

Usual Pediatric Dose for Mycobacterium avium-intracellulare -- Prophylaxis:

Immediate-release:
Prevention of disseminated MAC disease in patients with advanced HIV infection:
16 years or older: 1200 mg orally once a week; may be combined with the approved dosage regimen of rifabutin

(Not approved by FDA)

ATS, CDC, NIH, IDSA, and AAP recommendations for HIV-exposed and HIV-infected infants and children:
Primary prevention of MAC infections:
Preferred regimen: 20 mg/kg (maximum: 1200 mg/dose) orally once a week
Alternative regimen: 5 mg/kg (maximum: 250 mg/dose) orally once a day

Secondary prevention of MAC infections: 5 mg/kg (maximum: 250 mg/dose) orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen

ATS, CDC, NIH, and IDSA recommendations for HIV-infected adolescents:
Primary prevention of disseminated MAC disease: 1200 mg orally once a week

Chronic maintenance therapy (secondary prophylaxis) for disseminated MAC disease: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as alternative therapy

Secondary prophylaxis is usually continued for life; however, discontinuation may be considered in patients with sustained immune recovery in response to antiretroviral therapy.

Usual Pediatric Dose for Mycobacterium avium-intracellulare -- Treatment:

Immediate-release:
Treatment of disseminated MAC infections in patients with advanced HIV infection:
16 years or older: 600 mg orally once a day plus ethambutol

Other antimycobacterial drugs with in vitro activity against MAC may be added to this regimen at the physician's discretion.

(Not approved by FDA)

ATS, CDC, NIH, IDSA, and AAP recommendations for HIV-exposed and HIV-infected infants and children:
Treatment of MAC infections: 10 to 12 mg/kg (maximum: 500 mg/dose) orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen

ATS, CDC, NIH, and IDSA recommendations for HIV-infected adolescents:
Treatment of disseminated MAC infections: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen

Combination therapy with at least 2 drugs is recommended. Chronic suppressive therapy (secondary prophylaxis) is recommended after initial therapy.

Usual Pediatric Dose for STD Prophylaxis:

(Not approved by FDA)

CDC recommendations for adolescent sexual assault victims:
Immediate-release: 1 g orally as a single dose, in conjunction with metronidazole plus (ceftriaxone or cefixime)

Usual Pediatric Dose for Pertussis Prophylaxis:

(Not approved by FDA)

CDC recommendations for treatment and postexposure prophylaxis:
Immediate-release:
Less than 1 month: 10 mg/kg orally once a day for 5 days
1 to 5 months: 10 mg/kg orally once a day for 5 days
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

Usual Pediatric Dose for Pertussis:

(Not approved by FDA)

CDC recommendations for treatment and postexposure prophylaxis:
Immediate-release:
Less than 1 month: 10 mg/kg orally once a day for 5 days
1 to 5 months: 10 mg/kg orally once a day for 5 days
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

Usual Pediatric Dose for Lyme Disease -- Erythema Chronicum Migrans:

(Not approved by FDA)

IDSA recommendations for children:
Early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or advanced atrioventricular heart block:
Immediate-release: 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 to 10 days

Azithromycin is recommended when first-line agents (oral doxycycline, amoxicillin, or cefuroxime) cannot be used. Patients should be monitored closely to ensure resolution of clinical manifestations.

Usual Pediatric Dose for Babesiosis:

(Not approved by FDA)

Immediate-release:
IDSA recommendations for children: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day for a total of 7 to 10 days, in combination with atovaquone

Alternatively, a dosage of 12 mg/kg (maximum: 600 mg/dose) orally once a day for 7 to 10 days in combination with atovaquone has been recommended for pediatric patients.

Usual Pediatric Dose for Bacterial Endocarditis Prophylaxis:

(Not approved by FDA)

AHA recommendations for children allergic to penicillins:
Immediate-release: 15 mg/kg (maximum: 500 mg) orally as a single dose 30 to 60 minutes prior to procedure

Usual Pediatric Dose for Toxoplasmosis:

(Not approved by FDA)

CDC, NIH, and IDSA recommendations for HIV-infected adolescents:
Immediate-release: 900 to 1200 mg orally once a day, in conjunction with pyrimethamine and leucovorin
Duration: At least 6 weeks; longer duration if disease is extensive or response is incomplete at 6 weeks

Azithromycin is recommended as an alternative regimen.

Usual Pediatric Dose for Typhoid Fever:

(Not approved by FDA)

Immediate-release:
3 years or older: 20 mg/kg (maximum: 1 g/dose) orally once a day for 5 to 7 days

Alternatively, a dosage of 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 days has been recommended.

Usual Pediatric Dose for Cystic Fibrosis:

(Not approved by FDA)

Chronic Pseudomonas aeruginosa infections in CF patients:
6 years or older, weight 25 kg or more and adolescents:
25 to less than 40 kg: 250 mg orally on Mondays, Wednesdays, Fridays
40 kg or more: 500 mg orally on Mondays, Wednesdays, Fridays

If side effects are intolerable, the dose should be decreased to twice a week, or if necessary, once a week.

Usual Pediatric Dose for Upper Respiratory Tract Infection:

(Not approved by FDA)

Immediate-release:
6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5

What other drugs will affect azithromycin?

Many drugs can interact with azithromycin. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with azithromycin, especially:

  • droperidol;

  • methadone;

  • nelfinavir;

  • another antibiotic--clarithromycin, erythromycin, moxifloxacin, pentamidine;

  • a blood thinner (warfarin, Coumadin);

  • cancer medicine--arsenic trioxide, vandetanib;

  • an antidepressant--citalopram, escitalopram;

  • anti-malaria medication--chloroquine, halofantrine;

  • heart rhythm medicine--amiodarone, disopyramide, dofetilide, flecainide, ibutilide, procainamide, quinidine, sotalol; or

  • medicine to treat a psychiatric disorder--chlorpromazine, haloperidol, mesoridazine, pimozide, thioridazine.

This list is not complete and many other drugs can interact with azithromycin. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.

Where can I get more information?

  • Your pharmacist can provide more information about azithromycin.
  • Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
  • Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 17.02. Revision Date: 2013-06-06, 9:44:07 AM.

Hide
(web4)